首页> 美国卫生研究院文献>Antimicrobial Agents and Chemotherapy >Macrolide-Resistant Mycoplasma pneumoniae in Adults in Zhejiang China
【2h】

Macrolide-Resistant Mycoplasma pneumoniae in Adults in Zhejiang China

机译:浙江省成人抗大环内酯类肺炎支原体

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Mycoplasma pneumoniae is a major pathogen causing community-acquired pneumoniae (CAP), which is generally treated with macrolides. In recent years, however, although macrolide-resistant M. pneumoniae has been reported frequently, particularly in China, very little is known about the prevalence of macrolide-resistant M. pneumoniae infection in adults. In this study, we survey the macrolide-resistant M. pneumoniae in adults in Zhejiang province and characterize the mechanisms of resistance to macrolide. Six hundred fifty throat swab samples were collected from adult patients with CAP from January 2012 to August 2014. These samples were assayed by nested PCR and then cultivated for M. pneumoniae. All isolates were sequenced to determine the mutation in domain V of the 23S rRNA gene. The activities of 10 antibiotics against macrolide-resistant M. pneumoniae isolates were also investigated in vitro. Moreover, restriction fragment length polymorphism (RFLP) analysis of the amplified P1 gene was used to type 50 resistant strains. One hundred percent (71/71) of M. pneumoniae strains isolated from adults with CAP were resistant to erythromycin (MIC = 128 to >256 μg/ml), clarithromycin (MIC = 128 to >256 μg/ml), and azithromycin (MIC = 32 to >64 μg/ml). Furthermore, all macrolide-resistant M. pneumoniae strains identified had an A2063G mutation in domain V of the 23S rRNA gene. Forty-six resistant strains (92.0%) were classified into type I strain on the basis of P1 gene PCR-RFLP analysis. According to these findings, it is suggested that macrolide-resistant M. pneumoniae infection is very prevalence among adults in Zhejiang province. Thus, there is necessary to perform the epidemiological monitoring of macrolide-resistant M. pneumoniae in the future.
机译:肺炎支原体是引起社区获得性肺炎(CAP)的主要病原体,通常用大环内酯类药物治疗。然而,近年来,尽管经常报道了对大环内酯类耐药的肺炎支原体,特别是在中国,但对于成年人中对大环内酯类耐药的肺炎支原体感染的了解甚少。在这项研究中,我们调查了浙江省成人对大环内酯类耐药的肺炎支原体,并阐明了对大环内酯类耐药的机制。从2012年1月至2014年8月,从成年CAP病人中收集了650个咽拭子样本。这些样本通过巢式PCR分析,然后进行肺炎支原体培养。对所有分离物进行测序以确定23S rRNA基因的结构域V中的突变。体外还研究了10种抗生素对大环内酯类耐药肺炎支原体分离株的活性。此外,扩增的P1基因的限制性片段长度多态性(RFLP)分析被用于50型耐药菌株。从患有CAP的成年人中分离出的肺炎支原体菌株中有100%(71/71)对红霉素(MIC = 128至> 256μg/ ml),克拉霉素(MIC = 128至> 256μg/ ml)和阿奇霉素( MIC = 32至> 64μg/ ml)。此外,鉴定出的所有抗大环内酯类肺炎支原体菌株在23S rRNA基因的V区均具有A2063G突变。根据P1基因PCR-RFLP分析,将46种抗性菌株(92.0%)分类为I型菌株。根据这些发现,表明浙江省成年人中大环内酯类耐药的肺炎支原体感染非常普遍。因此,将来有必要进行对大环内酯类耐药的肺炎支原体的流行病学监测。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号